Coya Therapeutics, Inc. (COYA) Price & Analysis

Compare

87 Followers

COYA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.65 - $10.24

Previous CloseN/A

Volume16.99K

Average Volume (3M)97.60K

Market Cap

N/A

Enterprise Value$66.41M

Total Cash (Recent Filing)$29.76B

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.37

Next Earnings

Nov 05, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.36

Shares Outstanding16,725,080

10 Day Avg. Volume84,662

30 Day Avg. Volume97,604

Financial Highlights & Ratios

PEG Ratio-0.24

Price to Book (P/B)2.21

Price to Sales (P/S)24.57

P/FCF Ratio-8.49

Enterprise Value/Market CapN/A

Enterprise Value/Revenue156.83

Enterprise Value/Gross Profit164.82

Enterprise Value/Ebitda-0.01

Forecast

1Y Price Target

$16.60

Price Target Upside193.29% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentCoya Therapeutics announced the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).

Financial StabilityCoya Therapeutics ended 2Q25 with $29.8M in cash and cash equivalents, which along with the expected milestone payments from DRL should be sufficient to fund operations into at least 2H26 based on forecasts.

Regulatory MilestonesThe FDA's acceptance of the IND triggers a $4.2M milestone payment to Coya from its strategic partner, Dr. Reddy's Laboratories.

Bears Say

Market AdoptionRisks include clinical setbacks involving COYA 302 in ALS and/or AD, inability to advance into pivotal development, failure to secure U.S. regulatory approval, and poorer-than-anticipated commercial uptake.

Regulatory ApprovalRisks include clinical setbacks involving COYA 302 in ALS and/or AD, and failure to secure U.S. regulatory approval.

Risks And SetbacksRisks include clinical setbacks involving COYA 302 in ALS and/or AD, failure to secure U.S. regulatory approval, and possible medium-term dilution risk.

Coya Therapeutics, Inc. News

Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study

Coya Therapeutics (COYA) announces completion of patient enrollment of an investigator-initiated, proof-of-concept, open-label study with low-dose IL-2 and...

2d ago

COYA

Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302

Coya Therapeutics (COYA) announced the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study...

9d ago

COYA

Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study

Coya Therapeutics (COYA) announced results of a study designed to evaluate the effects of COYA 303, Coya’s investigational...

15d ago

COYA

Coya Therapeutics’ COYA 302 ALS trial accepted by NEALS research consortium

Coya Therapeutics (COYA)’ upcoming Phase 2 clinical trial to evaluate the efficacy and safety of COYA 302 in...

27d ago

COYA

Positive Outlook for Coya Therapeutics Driven by Promising COYA-302 Clinical Developments and Regulatory Support

Analyst Thomas Shrader from BTIG maintained a Buy rating on Coya Therapeutics, Inc. and keeping the price target...

17h ago

COYA

Promising Outlook for COYA 302 Amidst Phase 2 Trial and Near-Term Catalysts Justifies Buy Rating

Coya Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

8d ago

COYA

Coya Therapeutics Receives $4.2M Milestone Payment

An update from Coya Therapeutics, Inc. ( ($COYA) ) is now available. On August 29, 2025, Coya Therapeutics,...

29d ago

COYA

Coya receives $4.2M milestone payment after FDA approval of IND for Coya 302

Coya Therapeutics (COYA) announces that the FDA has accepted its Investigational New Drug, or IND, application for COYA...

1M ago

COYA

Positive Outlook for Coya Therapeutics Amid Promising Developments and Financial Stability

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Coya Therapeutics, Inc. and keeping the price...

1M ago

COYA

Coya Therapeutics Reports Increased Losses Amid Development Focus

Coya Therapeutics, Inc. ( ($COYA) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

COYA

Coya Therapeutics files $75M mixed securities shelf

08:36 EDT Coya Therapeutics (COYA) files $75M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

COYA

Coya Therapeutics Highlights Q2 2025 Financial Results

Coya Therapeutics, Inc. ( ($COYA) ) has provided an update. Coya Therapeutics reported its financial results for the...

2M ago

COYA

Coya Therapeutics reports Q2 EPS (36c), consensus (43c)

Reports Q2 revenue $200K, consensus $668.57K. As of June 30, 2025, Coya had cash and cash equivalents of...

2M ago

COYA

Is COYA a Buy, Before Earnings?

Coya Therapeutics, Inc. (COYA) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street...

2M ago

COYA

COYA FAQ

What was Coya Therapeutics, Inc.’s price range in the past 12 months?

Coya Therapeutics, Inc. lowest stock price was $4.65 and its highest was $10.24 in the past 12 months.

What is Coya Therapeutics, Inc.’s market cap?

Currently, no data Available

When is Coya Therapeutics, Inc.’s upcoming earnings report date?

Coya Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 35 days.

How were Coya Therapeutics, Inc.’s earnings last quarter?

Coya Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.419 by $0.059.

Is Coya Therapeutics, Inc. overvalued?

According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Coya Therapeutics, Inc. pay dividends?

Coya Therapeutics, Inc. does not currently pay dividends.

What is Coya Therapeutics, Inc.’s EPS estimate?

Coya Therapeutics, Inc.’s EPS estimate is -0.24.

How many shares outstanding does Coya Therapeutics, Inc. have?

Coya Therapeutics, Inc. has 16,725,080 shares outstanding.

What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?

Coya Therapeutics, Inc. reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.419. Following the earnings report the stock price went down -0.325%.

Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?

Currently, no hedge funds are holding shares in COYA

Company Description

Coya Therapeutics, Inc.

Coya Therapeutics, Inc. (COYA) is a biotechnology company focused on developing innovative therapies for neurodegenerative and autoimmune diseases. The company leverages its expertise in regulatory T-cell (Treg) technology to create treatments that address the underlying causes of these conditions. Coya's core products are designed to modulate the immune system to enhance the body's natural ability to combat disease, offering new hope for patients with limited treatment options.

Coya Therapeutics, Inc. (COYA) Earnings & Revenues

Historic Earnings Reports

COYA Stock 12 Month Forecast

Average Price Target

$16.60

▲(193.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.52,7.556923076923077,8.593846153846155,9.63076923076923,10.667692307692308,11.704615384615385,12.741538461538461,13.778461538461539,14.815384615384616,15.852307692307694,16.88923076923077,17.926153846153845,18.963076923076926,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.52,7.295384615384615,8.07076923076923,8.846153846153847,9.621538461538462,10.396923076923077,11.172307692307694,11.947692307692309,12.723076923076924,13.49846153846154,14.273846153846154,15.049230769230771,15.824615384615386,{"y":16.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.52,7.095384615384615,7.67076923076923,8.246153846153845,8.821538461538461,9.396923076923077,9.972307692307691,10.547692307692307,11.123076923076923,11.698461538461538,12.273846153846154,12.849230769230768,13.424615384615384,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.03,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >